James Conway

Dr. James Conway

Turku Bioscience Centre
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in Nature Methods
Verified
Journal Article
Open access
PDF file
DEDmitry Ershov
Dmitry Ershov
MPMinh-Son Phan
Minh-Son Phan
JPJoanna W. Pylvänäinen
Joanna W. Pylvänäinen
SRStéphane U. Rigaud
Stéphane U. Rigaud
LBLaure Le Blanc
Laure Le Blanc
JTJean-Yves Tinevez
Jean-Yves Tinevez
TrackMate is an automated tracking software used to analyze bioimages and is distributed as a Fiji plugin. Here, we introduce a new version of TrackMate. TrackMate 7 is built to address the broad spectrum of modern challenges researchers face by integrating state-of-the-art segmentation algorithms into tracking pipelines. We illustrate qualitatively and quantitatively that these new capabilities function effectively across a wide range of bio-imaging experiments.

1 May 2018 in Cell Metabolism
Verified
Journal Article
Closed access
Graeme LancasterGraeme Lancaster
Graeme Lancaster
KLKatherine G. Langley
Katherine G. Langley
NBNils Anton Berglund
Nils Anton Berglund
HKHelene L. Kammoun
Helene L. Kammoun
SRSaskia Reibe
Saskia Reibe
Mark A FebbraioMark A Febbraio
Mark A Febbraio

5 April 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CVClaire Vennin
Claire Vennin
VCVenessa T. Chin
Venessa T. Chin
SWSean Warren
Sean Warren
MLMorghan C. Lucas
Morghan C. Lucas
DHDavid Herrmann
David Herrmann
PTPaul Timpson
Paul Timpson
Fine-tuned manipulation of tumor tension and vasculature enhances response to chemotherapy and impairs metastatic spread in pancreatic cancer.

17 April 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
JCJames Conway
James Conway
NCNeil Carragher
Neil Carragher
PTPaul Timpson
Paul Timpson

5 June 2014 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
DHDavid Herrmann
David Herrmann
JCJames Conway
James Conway
CVClaire Vennin
Claire Vennin
AMAstrid Magenau
Astrid Magenau
WHWilliam E. Hughes
William E. Hughes
PTPaul Timpson
Paul Timpson
Basic in vitro systems can be used to model and assess complex diseases, such as cancer. Recent advances in this field include the incorporation of multiple cell types and extracellular matrix proteins into three-dimensional (3D) models to recapitulate the structure, organization and functionality of live tissue in situ. Cells within such a 3D environment behave very differently from cells on two-dimensional (2D) substrates, as cell–matrix interactions trigger signalling pathways and cellular responses in 3D, which may not be observed in 2D. Thus, the use of 3D systems can be advantageous for the assessment of disease progression over 2D set-ups alone. Here, we highlight the current advantages and challenges of employing 3D systems in the study of cancer and provide an overview to guide the appropriate use of distinct models in cancer research.

1 October 2017 in Cell Reports
Verified
Journal Article
Open access
Max NobisMax Nobis
Max Nobis
DHDavid Herrmann
David Herrmann
SWSean C. Warren
Sean C. Warren
SKShereen Kadir
Shereen Kadir
WLWilfred Leung
Wilfred Leung
PTPaul Timpson
Paul Timpson
The small GTPase RhoA is involved in a variety of fundamental processes in normal tissue. Spatiotemporal control of RhoA is thought to govern mechanosensing, growth, and motility of cells, while its deregulation is associated with disease development. Here, we describe the generation of a RhoA-fluorescence resonance energy transfer (FRET) biosensor mouse and its utility for monitoring real-time activity of RhoA in a variety of native tissues in vivo. We assess changes in RhoA activity during mechanosensing of osteocytes within the bone and during neutrophil migration. We also demonstrate spatiotemporal order of RhoA activity within crypt cells of the small intestine and during different stages of mammary gestation. Subsequently, we reveal co-option of RhoA activity in both invasive breast and pancreatic cancers, and we assess drug targeting in these disease settings, illustrating the potential for utilizing this mouse to study RhoA activity in vivo in real time.